Search Results - "Mclaughlin, Vallerie V"

An overview of the 6th World Symposium on Pulmonary Hypertension by Galiè, Nazzareno, McLaughlin, Vallerie V, Rubin, Lewis J, Simonneau, Gerald

“…Since 1973 the World Symposia on Pulmonary Hypertension (WSPH) proceedings have summarised the scientific advances and future needs in this field through the…”
Get full text

Risk stratification and medical therapy of pulmonary arterial hypertension by Galiè, Nazzareno, Channick, Richard N, Frantz, Robert P, Grünig, Ekkehard, Jing, Zhi Cheng, Moiseeva, Olga, Preston, Ioana R, Pulido, Tomas, Safdar, Zeenat, Tamura, Yuichi, McLaughlin, Vallerie V

“…Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with…”
Get full text

Management of Pulmonary Arterial Hypertension by McLaughlin, Vallerie V., MD, Shah, Sanjiv J., MD, Souza, Rogerio, MD, Humbert, Marc, MD, PhD

“…Abstract Pulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic…”
Get full text

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension by Hoeper, Marius M., Badesch, David B., Ghofrani, H. Ardeschir, Gibbs, J. Simon R., Gomberg-Maitland, Mardi, McLaughlin, Vallerie V., Preston, Ioana R., Souza, Rogerio, Waxman, Aaron B., Grünig, Ekkehard, Kopeć, Grzegorz, Meyer, Gisela, Olsson, Karen M., Rosenkranz, Stephan, Xu, Yayun, Miller, Barry, Fowler, Marcie, Butler, John, Koglin, Joerg, de Oliveira Pena, Janethe, Humbert, Marc

“…In this double-blind, randomized, placebo-controlled trial, sotatercept increased the exercise capacity of patients with pulmonary arterial hypertension…”
Get full text

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study by Coghlan, J Gerry, Denton, Christopher P, Grünig, Ekkehard, Bonderman, Diana, Distler, Oliver, Khanna, Dinesh, Müller-Ladner, Ulf, Pope, Janet E, Vonk, Madelon C, Doelberg, Martin, Chadha-Boreham, Harbajan, Heinzl, Harald, Rosenberg, Daniel M, McLaughlin, Vallerie V, Seibold, James R

“…Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective…”
Get more information

Selexipag for the Treatment of Pulmonary Arterial Hypertension by Sitbon, Olivier, Channick, Richard, Chin, Kelly M, Frey, Aline, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M, Lang, Irene M, Preiss, Ralph, Rubin, Lewis J, Di Scala, Lilla, Tapson, Victor, Adzerikho, Igor, Liu, Jinming, Moiseeva, Olga, Zeng, Xiaofeng, Simonneau, Gérald, McLaughlin, Vallerie V

“…Among over 1100 patients with pulmonary arterial hypertension who received selexipag, an oral selective IP prostacyclin-receptor agonist, or placebo, the risk…”
Get full text

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension by Galiè, Nazzareno, Barberà, Joan A, Frost, Adaani E, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M, McLaughlin, Vallerie V, Peacock, Andrew J, Simonneau, Gérald, Vachiery, Jean-Luc, Grünig, Ekkehard, Oudiz, Ronald J, Vonk-Noordegraaf, Anton, White, R. James, Blair, Christiana, Gillies, Hunter, Miller, Karen L, Harris, Julia H.N, Langley, Jonathan, Rubin, Lewis J

“…Patients with previously untreated pulmonary arterial hypertension who were randomly assigned to combination therapy with ambrisentan and tadalafil had a…”
Get full text

Updated Treatment Algorithm of Pulmonary Arterial Hypertension by Galiè, Nazzareno, MD, Corris, Paul A., MD, Frost, Adaani, MD, Girgis, Reda E., MD, Granton, John, MD, Jing, Zhi Cheng, MD, Klepetko, Walter, MD, McGoon, Michael D., MD, McLaughlin, Vallerie V., MD, Preston, Ioana R., MD, Rubin, Lewis J., MD, Sandoval, Julio, MD, Seeger, Werner, MD, Keogh, Anne, MD

“…The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes…”
Get full text

Treatment Goals of Pulmonary Hypertension by McLaughlin, Vallerie V., MD, Gaine, Sean Patrick, MD, PhD, Howard, Luke S., DPhil, Leuchte, Hanno H., MD, Mathier, Michael A., MD, Mehta, Sanjay, MD, Palazzini, Massimillano, MD, Park, Myung H., MD, Tapson, Victor F., MD, Sitbon, Olivier, MD, PhD

“…With significant therapeutic advances in the field of pulmonary arterial hypertension, the need to identify clinically relevant treatment goals that correlate…”
Get full text

Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension by Khanna, Dinesh, Gladue, Heather, Channick, Richard, Chung, Lorinda, Distler, Oliver, Furst, Daniel E., Hachulla, Eric, Humbert, Marc, Langleben, David, Mathai, Stephen C., Saggar, Rajeev, Visovatti, Scott, Altorok, Nezam, Townsend, Whitney, FitzGerald, John, McLaughlin, Vallerie V.

“…Objective Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTDs). Previous recommendations developed as…”
Get full text

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality by McLaughlin, Vallerie V., Hoeper, Marius M., Channick, Richard N., Chin, Kelly M., Delcroix, Marion, Gaine, Sean, Ghofrani, Hossein-Ardeschir, Jansa, Pavel, Lang, Irene M., Mehta, Sanjay, Pulido, Tomás, Sastry, B.K.S., Simonneau, Gérald, Sitbon, Olivier, Souza, Rogério, Torbicki, Adam, Tapson, Victor F., Perchenet, Loïc, Preiss, Ralph, Verweij, Pierre, Rubin, Lewis J., Galiè, Nazzareno

“…Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of…”
Get full text

Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension by Barst, Robyn J., MD, Gibbs, J. Simon R., MD, Ghofrani, Hossein A., MD, Hoeper, Marius M., MD, McLaughlin, Vallerie V., MD, Rubin, Lewis J., MD, Sitbon, Olivier, MD, Tapson, Victor F., MD, Galiè, Nazzareno, MD

“…Uncontrolled and controlled clinical trials with different compounds and procedures are reviewed to define the risk-benefit profiles for therapeutic options in…”
Get full text

Exercise Rehabilitation is Underutilized Among Veterans With Pulmonary Hypertension by Cascino, Thomas M., Schopfer, David W., Meyer, Craig S., Zhang, Ning, Barnes, Geoffrey D., McLaughlin, Vallerie V., Jackson, Elizabeth A., Whooley, Mary A.

Get full text

Treatment of pulmonary hypertension by Hoeper, Marius M, Prof, McLaughlin, Vallerie V, Prof, Dalaan, Abdullah M Al, MD, Satoh, Toru, Prof, Galiè, Nazzareno, Prof

“…Summary The most common forms of pulmonary hypertension are pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary…”
Get full text

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension by Oudiz, Ronald J., MD, Galiè, Nazzareno, MD, Olschewski, Horst, MD, Torres, Fernando, MD, Frost, Adaani, MD, Ghofrani, Hossein A., MD, Badesch, David B., MD, McGoon, Michael D., MD, McLaughlin, Vallerie V., MD, Roecker, Ellen B., PhD, Harrison, Brooke C., PhD, Despain, Darrin, MS, Dufton, Christopher, PhD, Rubin, Lewis J., MD

“…Objectives This study evaluated the safety and efficacy of ambrisentan for a period of 2 years in patients with pulmonary arterial hypertension (PAH)…”
Get full text

Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension by McLaughlin, Vallerie V, Oudiz, Ronald J, Frost, Adaani, Tapson, Victor F, Murali, Srinivas, Channick, Richard N, Badesch, David B, Barst, Robyn J, Hsu, Henry H, Rubin, Lewis J

“…Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). To evaluate the safety…”
Get full text

End Points and Clinical Trial Design in Pulmonary Arterial Hypertension by McLaughlin, Vallerie V., MD, Badesch, David B., MD, Delcroix, Marion, MD, PhD, Fleming, Thomas R., PhD, Gaine, Sean P., MD, PhD, Galiè, Nazzareno, MD, Gibbs, J. Simon R., MD, Kim, Nick H., MD, Oudiz, Ronald J., MD, Peacock, Andrew, MD, Provencher, Steeve, MD, MSc, Sitbon, Olivier, MD, Tapson, Victor F., MD, Seeger, Werner, MD

“…New and emerging therapies might provide benefit in patients with pulmonary arterial hypertension. Their efficacy and safety will be compared with existing…”
Get full text

Pulmonary Diseases and the Heart by HAN, Meilan K, MCLAUGHLIN, Vallerie V, CRINER, Gerard J, MARTINEZ, Fernando J

“…The complex nature of interactions between the pulmonary and cardiovascular systems is becoming increasingly appreciated. Pulmonary vascular abnormalities are…”
Get full text

Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era by Rubenfire, Melvyn, MD, Huffman, Mark D., MD, MPH, Krishnan, Sangeetha, MS, Seibold, James R., MD, Schiopu, Elena, MD, McLaughlin, Vallerie V., MD, FCCP

“…Background The impact of modern therapy on survival in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) is not clear. We sought…”
Get full text

Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension by Bhave, Nicole M., Visovatti, Scott H., Kulick, Brian, Kolias, Theodore J., McLaughlin, Vallerie V.

“…Transthoracic echocardiography (TTE) is a practical and widely used tool for risk stratification in pulmonary arterial hypertension (PAH). We hypothesized that…”
Get full text